GRM2 and schizophrenia: Preclinical trial studies indicated that mGluR2/3 agonists exhibited great efficiency in alleviating both positive and negative symptoms of schizophrenia with limited adverse side effects [7], [12], [66]–[68] although a recent Phase 2 trial exhibited a discouraging finding [69].